Tag:

startups

Latest Headlines

Latest Headlines

Pfizer, Novartis chip in on $17M round for an Atlas upstart focused on pain

The busy partners at Atlas Venture have gathered together a $17 million Series A for their latest biotech creation: Quartet Medicine, which pairs together two scientific founders who have been exploring the frontiers of pain management. This is Atlas' fourth maiden round for one of their biotech launches in a little more than a week, with Cambridge, MA-based Quartet joining Unum, Raze and Bicycle in a rare streak of startups. And there are likely some more to come.

Novartis joins an Atlas syndicate to back cancer drug upstart Raze

Atlas Venture is launching one of its newly built biotechs with a Series A of $24 million, a founding partner on the board, a pair of its entrepreneurs heading the crew and some marquee investors in the syndicate, which includes Novartis. They've begun a voyage of discovery with Raze Therapeutics, part of Atlas's growing fleet of startups, to see how far they can go down a pathway that offers its investigators a shot at throwing a monkey wrench into the metabolic processes cancer uses to thrive.

Venrock unveils a $450M new fund with eyes on biotech

Well-heeled venture capital firm Venrock has pieced together a 7th fund, banking $450 million in new investments as it sets out to grow its portfolio of promising startups.

Pfizer, Lilly and J&J chip in on $51M seed fund for New York biotechs

Three Big Pharma companies have helped come up with some seed money to start growing the first crop of biotechs in New York. Pfizer, Eli Lilly and J&J all chipped in to a $51 million fund from Accelerator Corp., which will now expand on the work it's been doing in Seattle to the East Side of Manhattan, recruiting upstarts to join investigators at the Alexandria Center for Life Science.

Atlas, NEA bankroll a $30M round for synthetic biology upstart Synlogic

This morning Atlas Venture and New Enterprise Associates announced that they have committed $29.4 million to launch Synlogic, a new Cambridge, MA-based upstart initially seeded last fall that has set out to build a platform that can create therapeutic microbes.

GeneCentric grabs $5M Series A to advance testing for personalized cancer treatments

Startup GeneCentric Diagnostics pulled in $5 million in new Series A financing, according to reports from The Herald-Sun and Dow Jones VentureWire, among other media organizations. The money will help the North Carolina startup advance further development of gene-based diagnostic products designed to enable personalized treatments.

PA startup's Series B will bring arthroscopic Dx needle through FDA clearance and launch

A three-year-old Pennsylvania startup pulled in the first tranche of a $11.6 million financing designed to help bring its first needle-based, minimally invasive diagnostic tool through regulatory clearance and commercial launch.

SynapDx and the Broad Institute link to use next-gen sequencing for better autism tests

Startup SynapDx will team with the famed Broad Institute of Harvard and MIT to advance next-generation DNA sequencing for more accurate and clinically useful autism diagnostic tools.

Sage snags $38M from A-list VCs to bankroll its seizure drugs

Cambridge, MA's Sage Therapeutics has hauled in a $38 million Series C, convincing a who's-who of biotech investors to pitch in as it pushes forward with a portfolio of central nervous system treatments.

UPDATED: Third Rock backs $14M round for Igenica's cancer-fighting antibodies

The antibody upstart Igenica has rounded up $14 million in venture cash to move its lead drug into the clinic. The Column Group, 5AM Ventures, OrbiMed and Third Rock Ventures all participated in the round.